Ken Griffin Aligos Therapeutics, Inc. Call Options Transaction History

Citadel Advisors LLC

  • $505 Billion
  • Q3 2024

Call Options

5 transactions
Quarter Operation Price Per call calls change calls Held SEC Form
Q2 2024

Aug 14, 2024
SELL
$0.35 - $1.07 $840 - $2,568
-2,400 Reduced 63.16%
1,400 $0
Q1 2024

May 15, 2024
BUY
$0.64 - $1.13 $2,432 - $4,294
3,800 New
3,800 $3,000
Q2 2023

Aug 14, 2023
SELL
$0.89 - $1.36 $7,031 - $10,744
-7,900 Reduced 62.7%
4,700 $4,000
Q1 2023

May 15, 2023
BUY
$0.87 - $2.11 $4,785 - $11,605
5,500 Added 77.46%
12,600 $10,000
Q4 2022

Feb 14, 2023
BUY
$0.89 - $28.0 $6,319 - $198,800
7,100 New
7,100 $6,000

Others Institutions Holding ALGS

# of Institutions
1
Shares Held
227K
Call Options Held
0
Put Options Held
0
View Full List

About Aligos Therapeutics, Inc.

ALGS Quotes by TradingView
  • Ticker ALGS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 39,717,000
  • Market Cap $1.66B
  • Description
  • Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses to develop novel therapeutics to address unmet medical needs in viral and liver diseases. Its lead drug candidate is ALG-010133, a s-antigen transport-inhibiting oligonucleotide polymer that is in Phase Ib clinical trial for the treatment of chronic hepatitis B (CHB);...
More about ALGS
Track Ken Griffin's Portfolio

Track Ken Griffin Portfolio

Follow Ken Griffin (Citadel Advisors LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email